Is Zebra Technologies (ZBRA) Quietly Redefining Its Edge With AI-Powered Healthcare Workflows?

• Zebra Technologies and Aiva Health recently announced a partnership to bring Aiva’s AI-powered, hands-free nurse assistant to Zebra’s HC20/HC50 mobile computers and new WS101-H wearable badge, integrating secure voice workflows directly into clinical devices.
• At the same time, Zebra is expanding its AI-enabled, wearable, and vision solutions for warehouses and factories, underscoring a push to embed automation and real-time intelligence across both healthcare and supply chain operations.
• Now we’ll examine how this expansion of AI-powered, hands-free workflows in healthcare could influence Zebra Technologies’ existing investment narrative.

We've uncovered the 11 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Zebra Technologies Investment Narrative Recap

To own Zebra Technologies, you need to believe that demand for automation, real time data and AI driven workflows will keep pulling its devices and software into mission critical roles across healthcare and supply chains. The Aiva Health partnership and new AI wearables fit cleanly into that story but do not fundamentally change the near term picture, where execution on acquisitions and integration of Elo and Photoneo still looks like the key catalyst, and tariff and macro pressures remain core risks.

The MODEX 2026 showcase is especially relevant here, because it highlights how Zebra is pairing AI enabled wearables like the WS501 R with its Frontline AI Suite across warehouses and factories. That breadth across healthcare and industrial workflows may matter for investors who are focused on whether Zebra can translate its acquisition heavy investment and higher R&D spend into more software rich, recurring revenue and better margin resilience if hardware cycles stay uneven.

Yet while the AI story is appealing, investors should still understand how concentrated exposure to tariffs and hardware heavy revenue could...

Read the full narrative on Zebra Technologies (it's free!)

Zebra Technologies' narrative projects $6.7 billion revenue and $815.0 million earnings by 2029. This requires 7.5% yearly revenue growth and about a $396 million earnings increase from $419.0 million today.

Uncover how Zebra Technologies' forecasts yield a $333.25 fair value, a 50% upside to its current price.

Exploring Other Perspectives

Against the upbeat consensus, the most pessimistic analysts assumed only about 6.7% annual revenue growth to roughly US$6.6 billion and earnings of about US$656 million by 2029, reminding you that even with AI partnerships like Aiva and warehouse wearables, opinions on tariff risks and margin pressure can differ sharply and that it is worth comparing several views before deciding what you believe.

Explore 4 other fair value estimates on Zebra Technologies - why the stock might be worth just $292.02!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Zebra Technologies research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Zebra Technologies research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Zebra Technologies' overall financial health at a glance.

Contemplating Other Strategies?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• The latest GPUs need a type of rare earth metal called Terbium and there are only 27 companies in the world exploring or producing it. Find the list for free.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 21 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• AI is about to change healthcare. These 31 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com